Bloodstream Infections in Pediatric Hematology/oncology Patients: a Single-center Study in Wuhan

Overview

Journal Front Cell Infect Microbiol

Specialties Cell Biology
Infectious Diseases
Microbiology

Date 2024 Dec 19

PMID 39698316

Authors

Ibrahim Ahmed Saleh Murshed

Lizhen Zhao

Wenzhi Zhang

Yuhong Yin

Ying Li

Yun Peng

Hongbo Chen

Xiaoyan Wu

Affiliations

Soon will be listed here.

Abstract

Bloodstream infections (BSIs) are a critical concern in pediatric onco-hematological patients undergoing chemotherapy or hematopoietic stem cell transplantation (HSCT), leading to a major impact on morbidity, long-term hospitalization, and mortality. We retrospectively analyzed 202 BSIs in 145 patients, consisting of 128 with hematological malignancies, one with a solid tumor, and 16 with non-malignant hematological diseases. We collected data on patient demographics, clinical characteristics, pathogen distribution, and antimicrobial pathogen susceptibility. Gram-positive infections were the most frequent at (58.4%), followed by gram-negative (41%), and fungal infections (0.5%). Particularly, the majority of these infections occurred during the induction phase of chemotherapy, where 94 (46.5%) BSI episodes were recorded, predominantly in neutropenic patients (88.3%). The consolidation phase experienced lower BSIs (11.8%); among these patients (54.1%) were non-neutropenic. BSIs observed in (23.7%) of patients in the maintenance phase, with a higher proportion (66.6%) being neutropenic. Among the 7 patients who underwent HSCT, BSIs occurred in (4.9%) cases, mainly (70%) due to neutropenia. The most prevalent pathogens were Staphylococcus epidermidis (19.8%), Staphylococcus hominis (16.3%), and Escherichia coli (8.4%). The study highlights the critical need for vigilant monitoring and customized infection management strategies to enhance patient outcomes across chemotherapy phases and HSCT.

References

Lakshmaiah K, Malabagi A, Govindbabu , Shetty R, Sinha M, Jayashree R . Febrile Neutropenia in Hematological Malignancies: Clinical and Microbiological Profile and Outcome in High Risk Patients. J Lab Physicians. 2015; 7(2):116-20. PMC: 4559624. DOI: 10.4103/0974-2727.163126. View

Nordmann P, Naas T, Poirel L . Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011; 17(10):1791-8. PMC: 3310682. DOI: 10.3201/eid1710.110655. View

Gafter-Gvili A, Fraser A, Paul M, Vidal L, Lawrie T, van de Wetering M . Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012; 1:CD004386. PMC: 4170789. DOI: 10.1002/14651858.CD004386.pub3. View

Garcia-Vidal C, Cardozo-Espinola C, Puerta-Alcalde P, Marco F, Tellez A, Aguero D . Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance. PLoS One. 2018; 13(6):e0199531. PMC: 6023133. DOI: 10.1371/journal.pone.0199531. View

Freifeld A, Bow E, Sepkowitz K, Boeckh M, Ito J, Mullen C . Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011; 52(4):e56-93. DOI: 10.1093/cid/cir073. View

Kakoullis L, Papachristodoulou E, Chra P, Panos G . Mechanisms of Antibiotic Resistance in Important Gram-Positive and Gram-Negative Pathogens and Novel Antibiotic Solutions. Antibiotics (Basel). 2021; 10(4). PMC: 8069106. DOI: 10.3390/antibiotics10040415. View

Routsi C, Gkoufa A, Arvaniti K, Kokkoris S, Tourtoglou A, Theodorou V . De-escalation of antimicrobial therapy in ICU settings with high prevalence of multidrug-resistant bacteria: a multicentre prospective observational cohort study in patients with sepsis or septic shock. J Antimicrob Chemother. 2020; 75(12):3665-3674. DOI: 10.1093/jac/dkaa375. View

Mikulska M, Viscoli C, Orasch C, Livermore D, Averbuch D, Cordonnier C . Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect. 2013; 68(4):321-31. DOI: 10.1016/j.jinf.2013.12.006. View

Tamma P, Cosgrove S, Maragakis L . Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev. 2012; 25(3):450-70. PMC: 3416487. DOI: 10.1128/CMR.05041-11. View

10.

Russotto V, Cortegiani A, Graziano G, Saporito L, Raineri S, Mammina C . Bloodstream infections in intensive care unit patients: distribution and antibiotic resistance of bacteria. Infect Drug Resist. 2015; 8:287-96. PMC: 4536838. DOI: 10.2147/IDR.S48810. View

11.

Mokart D, Slehofer G, Lambert J, Sannini A, Chow-Chine L, Brun J . De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study. Intensive Care Med. 2013; 40(1):41-9. DOI: 10.1007/s00134-013-3148-9. View

12.

Islas-Munoz B, Volkow-Fernandez P, Ibanes-Gutierrez C, Villamar-Ramirez A, Vilar-Compte D, Cornejo-Juarez P . Bloodstream infections in cancer patients. Risk factors associated with mortality. Int J Infect Dis. 2018; 71:59-64. DOI: 10.1016/j.ijid.2018.03.022. View

13.

Karanika S, Paudel S, Grigoras C, Kalbasi A, Mylonakis E . Systematic Review and Meta-analysis of Clinical and Economic Outcomes from the Implementation of Hospital-Based Antimicrobial Stewardship Programs. Antimicrob Agents Chemother. 2016; 60(8):4840-52. PMC: 4958232. DOI: 10.1128/AAC.00825-16. View

14.

Castagnola E, Bagnasco F, Mesini A, Agyeman P, Ammann R, Carlesse F . Antibiotic Resistant Bloodstream Infections in Pediatric Patients Receiving Chemotherapy or Hematopoietic Stem Cell Transplant: Factors Associated with Development of Resistance, Intensive Care Admission and Mortality. Antibiotics (Basel). 2021; 10(3). PMC: 8000765. DOI: 10.3390/antibiotics10030266. View

15.

Darby E, Trampari E, Siasat P, Gaya M, Alav I, Webber M . Molecular mechanisms of antibiotic resistance revisited. Nat Rev Microbiol. 2022; 21(5):280-295. DOI: 10.1038/s41579-022-00820-y. View

16.

Meryk A, Kropshofer G, Bargehr C, Knoll M, Hetzer B, Lass-Florl C . Which Type of Empiric Antibiotic Therapy is Appropriate? A 20-Year Retrospective Study of Bloodstream Infections in Childhood Cancer. Infect Dis Ther. 2021; 10(2):789-800. PMC: 8116419. DOI: 10.1007/s40121-021-00427-5. View

17.

Kapoor G, Sachdeva N, Jain S . Epidemiology of bacterial isolates among pediatric cancer patients from a tertiary care oncology center in North India. Indian J Cancer. 2016; 51(4):420-4. DOI: 10.4103/0019-509X.175364. View

18.

Magiorakos A, Srinivasan A, Carey R, Carmeli Y, Falagas M, Giske C . Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2011; 18(3):268-81. DOI: 10.1111/j.1469-0691.2011.03570.x. View

19.

Trehan A, Totadri S, Gautam V, Bansal D, Ray P . Invasive bacterial infections in a pediatric oncology unit in a tertiary care center. Indian J Cancer. 2016; 51(4):428-31. DOI: 10.4103/0019-509X.175368. View

20.

Ramphal R . Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis. 2004; 39 Suppl 1:S25-31. DOI: 10.1086/383048. View